A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...
The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC. The FDA ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...
Merck’s drug for chemo-induced nausea and vomiting has some new competition. On Thursday, the FDA approved Cinvanti from California’s Heron Therapeutics, and it’ll go up against the New Jersey pharma ...
EMEND (aprepitant) TriPack: 80mg + 125mg capsules The Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Emend (aprepitant; Merck) to include patients 12-17 ...
Merck & Co has been given the go ahead in the USA to market its Emend drug to treat nausea and vomiting in patients who undergo surgery, increasing the number of patients eligible to receive treatment ...
Merck Co. on Monday said its Emend drug to prevent chemotherapy-related nausea and vomiting was significantly more effective than a placebo in a Phase III study of cancer patients aged 6 months to 17 ...
Aprepitant 125mg; per pouch; pwd for oral susp after reconstitution. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors with little or no affinity for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results